{
    "title": "106_hr3274",
    "content": "The \"Patients' Formulary Rights Act of 1999\" ensures patient protections against the abuse of formularies for prescription drugs, specifically in group health plans. It introduces standards relating to the use of formularies and therapeutic substitution. The \"Patients' Formulary Rights Act of 1999\" mandates that group health plans and health insurance issuers offering group coverage must provide notification to participants and healthcare professionals about formulary details and any changes, including deletions. The \"Patients' Formulary Rights Act of 1999\" requires group health plans and health insurance issuers to disclose information about formulary changes, including therapeutic substitution practices. The \"Patients' Formulary Rights Act of 1999\" mandates disclosure of formulary details, including drug lists, access to nonformulary drugs, payment for nonformulary drugs, and decision-making processes for formulary inclusion. The \"Patients' Formulary Rights Act of 1999\" requires disclosure of formulary information, including coverage details, cost-sharing for prescription drugs, limits on payments, and definition of formulary. The \"Patients' Formulary Rights Act of 1999\" mandates that group health plans must comply with notice requirements regarding formulary limitations on drug coverage. Amendments to the Employee Retirement Income Security Act of 1974 also require adherence to these regulations. ERISA amendments require compliance with formulary limitations on drug coverage for group health plans. SEC. 714 outlines standards for the use of formularies and therapeutic substitution. Group health plans and health insurance issuers offering group health insurance coverage are required to notify participants, beneficiaries, and enrollees about formularies before enrollment and provide information to healthcare professionals prescribing drugs. They must also inform them of any changes in the formulary on a routine and annual basis. Group health plans and health insurance issuers must provide information on formularies to participants, beneficiaries, and enrollees before enrollment. They are also required to notify healthcare professionals prescribing drugs about any changes in the formulary. The information includes details on therapeutic substitution practices allowed under the plan or coverage. The formulary must include a list of prescription drugs, details on access to nonformulary drugs, and information on payment for nonformulary drugs under the plan or coverage. The section outlines cost-sharing, limits on payments, and notice requirements for group health plans regarding prescription drug coverage. The section outlines cost-sharing, limits on payments, and notice requirements for group health plans regarding prescription drug coverage. The summary description required under section 104(b)(1) for modifications must be provided within 60 days after the first plan year in which the requirement applies. The term 'formulary' includes any method by which a plan or issuer limits coverage for specific drugs. Amendments are made to sections 731(c) and 732(a) of the Act. Amendments are made to the table of contents in section 1 of the Act by inserting a new item after section 713. Amendments are made to the Internal Revenue Code of 1986 by inserting a new section 9813 regarding standards for formularies and therapeutic substitution. Group health plans must provide notification to participants and beneficiaries before enrollment regarding formulary information, notify them of any changes to the formulary on a routine basis, and ensure coverage for prescription drugs. The group health plan must inform participants about formulary details, including therapeutic substitution and formulary changes, to ensure coverage for prescription drugs. The group health plan must inform participants about formulary details, including therapeutic substitution and formulary changes, to ensure coverage for prescription drugs. Access to nonformulary drugs, payment for nonformulary drugs, cost-sharing, and limits on payments are key considerations for prescription drug coverage. Limits on payments for outpatient prescription drugs, including annual, lifetime, or diagnosis-based limits, are defined in the formulary. Amendments to the Code include expanding coverage under individual health insurance plans. SEC. 2753. STANDARD RELATING PATIENT FREEDOM OF CHOICE. The provisions of section 2707(a) apply to health insurance coverage in the individual market. A health insurance issuer must comply with notice requirements under the Employee Retirement Income Security Act. Amendments are made to sections 2762(b)(2) and 1852 of the Social Security Act. The Medicare+Choice organization must comply with formulary requirements similar to those for health insurance coverage in group health plans. These requirements do not supersede other Medicare+Choice plan requirements unless the Secretary determines they are less stringent and do not duplicate existing requirements. Effective dates apply to group health plans and insurance coverage. The amendments made by subsection (a) apply to group health plans starting on or after January 1, 2001. The amendments made by subsection (b) apply to individual health insurance coverage and Medicare+Choice plans offered on or after the same date, with an exception for group health plans under collective bargaining agreements ratified before the Act's enactment. The amendments made by subsection (a) do not apply to plan years before the later of the termination of collective bargaining agreements or January 1, 2001. Plan amendments made to conform to requirements added by subsection (a) under collective bargaining agreements are not considered terminations of such agreements. Coordination of administration is ensured by the Secretaries of Labor, Treasury, and Health and Human Services. The Secretaries of Labor, Treasury, and Health and Human Services must ensure that regulations, rulings, and interpretations are administered consistently and that enforcement policies are coordinated to avoid duplication and prioritize enforcement efforts."
}